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Inhibition of the chemokine receptor CXCR4 in combination with
blockade of the PD-1/PD-L1 T cell checkpoint induces T cell infiltra-
tion and anticancer responses in murine and human pancreatic
cancer. Here we elucidate the mechanism by which CXCR4 inhibi-
tion affects the tumor immune microenvironment. In human im-
mune cell-based chemotaxis assays, we find that CXCL12-
stimulated CXCR4 inhibits the directed migration mediated by
CXCR1, CXCR3, CXCR5, CXCR6, and CCR2, respectively, chemokine
receptors expressed by all of the immune cell types that partici-
pate in an integrated immune response. Inhibiting CXCR4 in an
experimental cancer medicine study by 1-wk continuous infusion
of the small-molecule inhibitor AMD3100 (plerixafor) induces an
integrated immune response that is detected by transcriptional
analysis of paired biopsies of metastases from patients with micro-
satellite stable colorectal and pancreatic cancer. This integrated
immune response occurs in three other examples of immune-
mediated damage to noninfected tissues: Rejecting renal allo-
grafts, melanomas clinically responding to anti-PD1 antibody
therapy, and microsatellite instable colorectal cancers. Thus, sig-
naling by CXCR4 causes immune suppression in human pancreatic
ductal adenocarcinoma and colorectal cancer by impairing the
function of the chemokine receptors that mediate the intratu-
moral accumulation of immune cells.
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T cell checkpoint antagonists that target the regulatory mem-brane proteins on T cells, CTLA-4 and PD-1, have demon-
strated the therapeutic potential of the immune system in cancer.
Clinical responses, however, have been limited to subsets of
patients with certain cancers (1–4). Lack of cancer cell antige-
nicity (5), dysfunction of cytotoxic CD8+ T cells (6), and systemic
immune modulation (7, 8) have been some of the potential ex-
planations for resistance of these cancers to T cell checkpoint
inhibitors. A more general immunological principle in which
mesenchymal cells may control the immune response to immu-
nogenic epithelial tissues should also be considered (9).
The presence of tertiary lymphoid structures (TLSs) in human
adenocarcinomas correlates with better long-term clinical out-
come and clinical response to T cell-checkpoint inhibitors (10–13),
suggesting that organized intratumoral lymphoid structures pro-
mote antitumor immune reactions. Mesenchymal stromal cells
organize B and T cells in both secondary and TLSs mainly by
producing chemokines: CCL19 and CCL21 from fibroblastic re-
ticular cells (FRCs) recruit CCR7-expressing lymphocytes and
dendritic cells (DCs), and CXCL13 from follicular DCs (FDCs)
attracts CXCR5-expressing T and B cells (14). Notably, these two
stromal cell types develop from an embryonic precursor that ex-
presses the membrane protein, fibroblast activation protein-α
(FAP), and may be developmentally related to the FAP-expressing
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fibroblastic stromal cell type that resides in solid tumors, which is
termed the cancer-associated fibroblast (CAF) (15–18). CAFs also
affect the trafficking of lymphocytes by producing a chemokine,
CXCL12 (19), but in a manner that opposes the effects of
lymphoid tissue stromal cells by suppressing the intratumoral
accumulation of T cells (20). Indeed, continuous inhibition of
CXCR4 in a mouse model of pancreatic cancer leads to T cell
infiltration of the tumors and results in response to anti–PD-L1
antibody administration (20). Therefore, whether the tumor
stroma supports or suppresses immune activation may depend on
the relative contributions of these related stromal cell types. A
predominance of CAFs would suppress local immunity, whereas
the presence of FRCs and FDCs and the development of TLSs
would enhance intratumoral immunity. This concept has been
supported by preclinical studies in which immune control of tumor
growth in mice occurred after FAP+ CAFs were conditionally
depleted (18, 20).
Here we report the results from a proof-of-concept experi-
mental medicine study in which we tested the immunological
consequences of inhibiting CXCR4 in patients with cancers that
have historically resisted immunotherapy, microsatellite stable
(MSS) colorectal cancer (CRC) or pancreatic ductal adenocar-
cinoma (PDA). We report that continuous administration for 1
wk of AMD3100 (plerixafor, Mozobil), a small-molecule inhib-
itor of CXCR4, promotes an integrated immune response
(INTIRE) in metastatic lesions from these patients.
Results
Colorectal and Pancreatic Cancer Cells Display a CXCL12 Coat. In
murine PDA tumors, cancer cells display a “coat” of CXCL12,
the chemokine that FAP+ CAFs produce to mediate their im-
mune suppressive activity (20). We assessed whether such a
CXCL12-coat is displayed on human PDA or CRC cancer cells
by examining tumor tissue microarrays. Fluorescently labeled
anti-CXCL12 antibodies stained the KRT19-expressing cancer
cells in formalin fixed paraffin-embedded (FFPE) tissue sections
of human PDA and CRC (Fig. 1).
CXCL12-Stimulated CXCR4 Inhibits the Directed Migration of Human
Immune Cells Mediated by Chemokine Receptors. We assessed
whether CXCL12 stimulation of CXCR4 altered the trafficking
of human immune cells by performing in vitro transwell migra-
tion assays using Boyden chambers. We generated human cell
lines that coexpressed CXCR4 with the chemokine receptors
that mediate the directed migration of innate and adaptive im-
mune cells: CXCR1 in Jurkat-CXCR4/CXCR1 cells, CXCR3 in
HSB2DP-CXCR4/CXCR3 cells, CXCR5 in Raji-CXCR4/
CXCR5 cells, CXCR6 in Jurkat-CXCR4/CXCR6 cells, and
CCR2 in Molm13-CXCR4/CCR2 cells, respectively (Fig. 2 and
SI Appendix, Fig. S1). These chemokine receptors and their re-
spective chemokines mediate the directed migration of: Neu-
trophils (CXCR1; CXCL8); T cells, DCs, and NK cells (CXCR3;
CXCL9 and CXCL10); B cells (CXCR5; CXCL13); tissue-
resident memory T cells (CXCR6; CXCL16); and monocytes
and macrophages (CCR2; CCL2) (Fig. 2). Including CXCL12 in
the upper chamber of the Boyden two-chamber assay inhibited
the migration of the human immune cells coexpressing CXCR4
with each one of the five other chemokine receptors toward its
relevant chemokine in the lower chamber. The inhibition was
dependent on CXCR4 expression (SI Appendix, Fig. S1) and was
unidirectional, in that stimulating the relevant immune cell lines
with their respective chemokines for CXCR1, CXCR3, CXCR5,
CXCR6, or CCR2 did not abolish the CXCR4-mediated che-
motactic response to CXCL12 (Fig. 2), with the exception of
partial inhibition by CXCL13. Incubating HSB2DP-CXCR4/
CXCR3 cells with CXCL12 followed by removal of the chemo-
kine restored the ability of cells to migrate in response to a
CXCL10 gradient (SI Appendix, Fig. S2).
AMD3100 Suppresses CXCL12-Stimulated Inhibition of Other
Chemokine Receptors. In previous murine studies, a continuous
plasma concentration of 2 μg/mL (4 μM) AMD3100 unmasked
anti-PDA immunity and led to reduced tumor growth rates and
synergy with anti–PD-L1 treatment (20). We thus examined the
effect of AMD3100 in chemotaxis studies across this range of
drug concentration in these human cell lines. AMD3100 fully
inhibited the CXCR4-mediated chemotactic responses of all
immune cell lines (SI Appendix, Fig. S3). The CXCR4 inhibitor
also fully reversed the inhibition by CXCL12 of the chemotactic
functions of CXCR1, CXCR5, and CXCR6 on the CXCR4-
expressing Jurkat cells (Fig. 3). The functions of CXCR3 and
CCR2 were only partially restored, which correlated with the
inhibitory effects of AMD3100 on CXCR3- and CCR2- medi-
ated chemotaxis in the absence of CXCL12 (SI Appendix, Fig.
S3). This inhibitory effect of AMD3100 may be caused by partial
agonism of CXCR4, which has been reported previously (21).
Since CXCR1, CXCR3, CXCR5, CXCR6, and CCR2 mediate
the trafficking of neutrophils, T cells, NK cells, DCs, B cells,
tissue-resident memory T cells, and monocytes, these observa-
tions suggest that AMD3100 may alter the trafficking of multiple
immune cell types within tumors, thereby inducing an INTIRE to
Fig. 1. The CXCL12-coat of human pancreatic and colorectal cancer cells. Sections of human pancreatic (PDA) and colorectal (CRC) adenocarcinoma were
stained with fluorescent antibodies to CXCL12, and to KRT19 to reveal cancer cells. The ratios shown in the top right corners of the photomicrographs indicate
the frequency of the observed staining relative to the total number of independent tumors that were assessed. (Scale bar, 50 μm.)
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Fig. 2. The effect of CXCL12-stimulated CXCR4 on chemokine receptor-mediated migration of human immune cells. (Left) The coexpression of CXCR4 with
(A) CXCR1, (B) CXCR3, (C) CXCR5, (D) CXCR6, and (E) CCR2 on human immune cell lines was evaluated by flow cytometry after staining with antibodies specific
for the relevant chemokine receptors. Gray peaks indicate isotype controls. (Center) The effect of CXCL12-stimulation of CXCR4 on the chemotactic responses
of A CXCR1-coexpressing Jurkat T lymphoblastoid cells to CXCL8, (B) CXCR3-coexpressing HSB2DP T lymphoblastoid cells to CXCL10, (C) CXCR5-coexpressing
Raji B lymphoblastoid cells to CXCL13, (D) CXCR6-coexpressing Jurkat T lymphoblastoid cells to CXCL16, and (E) CCR2-coexpressing Molm13 monocytoid cells
to CCL2 was assessed by including CXCL12 in the upper chamber (blue) and the other chemokines in the lower chamber (red) in the Boyden two-chamber
assay. (Right) The chemotaxis assays were performed with the five cell lines when the placement of the chemokines in the Boyden chambers was reversed. Bar
diagrams display mean and SEM (n = 3-4). Statistical analysis by Student’s t test: ***P < 0.001; ****P < 0.0001; ns, not significant.
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the cancer cells. We tested this hypothesis in an experimental
medicine study.
Experimental Medicine Study of Continuous AMD3100 Infusion: Study
Design, Recruitment, and Patient Characteristics. We targeted the
CXCL12/CXCR4 interaction using AMD3100 in an experimental
medicine study of the immunological role of CXCR4 signaling in
patients with MSS CRC and MSS PDA (NCT02179970).
AMD3100 has a plasma half-life of ∼8 h. To achieve continuous
inhibition of CXCR4, as has been recommended for other
chemokine receptors (22), AMD3100 was delivered by contin-
uous intravenous infusion for 7 d with the target steady-state
plasma concentration being ∼2 μg/mL (4 μM). We assessed the
pharmacokinetics, pharmacodynamics, and intratumoral im-
munological changes during treatment using serial blood tests,
clinical imaging modalities, and investigations from paired bi-
opsies taken prior to and at the end of the AMD3100 infusion
(SI Appendix, Figs. S4 and S5A).
We enrolled 26 patients at two centers, 24 at the Cambridge
University Hospitals National Health Service (NHS) Foundation
Trust and two at Weill Cornell Medicine/New York Presbyterian
Hospital. The patient eligibility criteria are shown in Methods.
The characteristics of all enrolled patients are summarized in
Table 1. On histopathological review, one patient was found to
have predominantly neuroendocrine cancer cells in the biopsy
tissue and this patient was therefore excluded from all analyses
other than the safety and pharmacokinetic analysis. The
remaining 25 patients had treatment-refractory, histologically
confirmed MSS PDA (n = 10) or MSS CRC (n = 15). An im-
portant inclusion criterion was the presence of a baseline lym-
phocyte count above the lower limit of normal (1.0 × 109/L) at
screening, because of concerns relating to adequate immune
status and resolution of immunosuppression after previous
chemotherapy. Twenty-four patients with CRC or PDA were
treated with AMD3100 (one registered patient did not com-
mence study drug, because of a disease related adverse event
[AE]): 17 in the dose escalation phase (2 PDA, 15 CRC) and 7
additional patients with PDA in the dose-expansion phase. We
confirmed the presence of the CXCL12-coat in all patients
enrolled in the dose-escalation phase who had evaluable tissue
(SI Appendix, Fig. S6).
Pharmacokinetic and Toxicity Results. The first dose level of
AMD3100 was an intravenous infusion at a rate of 20 μg/kg/h,
with subsequent patients enrolled at dose cohorts of 40, 80, and
120 μg/kg/h, using a 3+3 design. There were no dose-limiting
toxicities (DLTs) identified in the 20-, 40-, and 80-μg/kg/h dose
cohorts, but two patients experienced DLTs at the 120-μg/kg/h
dose (SI Appendix, Table S1). One patient had a vasovagal re-
action (grade 3) in the context of pain shortly after the day 8
biopsy and prior to completion of the AMD3100 infusion. One
patient who had peritoneal disease developed severe abdominal
pain (grade 3), hypotension (grade 3), and a vasovagal reaction
(grade 3) on day 2 of the infusion. Symptoms resolved within
24 h after discontinuing the drug, medications for pain control,
and intravenous fluids. Continuous infusion of AMD3100 has
been reported to be associated with vasovagal reactions (23), and
these events were classified as DLTs. A complete list of graded
AEs is included in SI Appendix (SI Appendix, Table S2).
In the trial of continuous intravenous infusion of AMD3100
for 1 wk in 40 patients with HIV, a single patient experienced
premature ventricular contractions (23). Thus, in the present
study, all patients were admitted for the initial 72 h of the
AMD3100 infusion for continuous cardiac telemetry monitoring,
Fig. 3. Inhibition by AMD3100 of the suppression mediated by CXCL12-stimulated CXCR4 of the function of other chemokine receptors. (A–E) The che-
motactic responses were assessed of the dual chemokine receptor-expressing human immune cells to the relevant chemokines in the absence or presence of
CXCL12, with increasing concentrations of AMD3100. The results are presented as percent of the chemotactic response in the absence of CXCL12 and
AMD3100. The mean and SEM are indicated.
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and Holter monitoring thereafter. No cardiac rhythm distur-
bances were identified at the 80-μg/kg/h infusion rate chosen for
the expansion phase. Minor changes (SI Appendix, Table S2) were
only possibly drug related, and there were no cardiac AEs that re-
quired drug interruption and all resolved without sequelae. There-
fore, hospital-based telemetry is not indicated in future studies using
this infusion protocol and static ECGs and ambulatory Holter
monitoring should provide sufficient cardiac monitoring.
The dose rate of 80 μg/kg/h yielded the target plasma level of
∼2 μg/mL (4 μM), and was chosen for the expansion cohort,
which resulted in a mean steady-state plasma concentration of
2.3 μg/mL (SD ± 0.9 μg/mL) AMD3100 in patients enrolled at
this dose rate (SI Appendix, Fig. S5B and Table S3). This infusion
rate was overall well tolerated (SI Appendix, Table S2).
Pharmacodynamic and Clinical Results. In accordance with the well-
characterized biological role of CXCL12/CXCR4 ligation for the
retention of hematopoietic stem cells (HSCs) and immature
leukocytes in the bone marrow (24), CD34+ and other leukocyte
populations were elevated during the period of AMD3100 in-
fusion. These changes had almost completely resolved by day 28
of the study, 20 d after discontinuation of the infusion (SI Ap-
pendix, Fig. S7). By conventional computed tomography (CT)
scanning on days 20 to 24, no complete or partial responses by
RECIST 1.1 were identified in 23 evaluable patients. Thirteen
patients (57%) had stable disease and 10 (43%) disease pro-
gression. Paired positron emission tomography (PET-CT) scans
were evaluable in 19 participants (12 escalation phase, 7 ex-
pansion phase). Of these, 11 participants had CRC and 8 PDA.
Clinically significant (defined as delta standardized uptake val-
ues mean weighted average [SUV MWA] ≥ 30%) changes were
seen in two participants. Both were patients with CRC (treated
at 40 μg/kg/h) and had a ≥30% increase in SUV MWA (71%
and 32%).
Immunological Analysis of Metastatic Tissue from Pretreatment and
On-Treatment Biopsies. We performed immunological analyses on
all patients who had sufficient sample material for comparative
histopathological and RNA studies (PDA n = 4; CRC n = 10) (SI
Appendix, Fig. S4). We first sought histological evidence of an
immunological response to CXCR4 inhibition by determining
the frequency of CD8+ T cells in paired pre- and end-of-treatment
biopsies of metastatic lesions. FFPE tissue sections were stained
with antibodies specific for CD8α and keratin (pan-CK), respec-
tively (Fig. 4A). There was a significant increase in the number
CD8+ T cells in the pan-CK+ cancer cell areas after treatment
with AMD3100 (SI Appendix, Fig. S8A). Frozen samples of dif-
ferent biopsy passes of the same metastatic lesions were subjected
to bulk RNA-sequencing (RNA-seq) analysis. The CD8a mRNA
levels were significantly up-regulated after AMD3100 adminis-
tration (SI Appendix, Fig. S8B), and significantly correlated with
the histopathologically determined CD8+ T cell frequencies
(Fig. 4B). This validation of the quantitative RNA-seq tran-
scriptomic set justified the further analysis of this comprehensive
source of immunological data.
By enrichment analysis of the RNA-seq data, we found that
continuous inhibition of CXCR4 by infusion of AMD3100 in-
duced intratumoral T and NK cell accumulation and activation
(Fig. 4C) and also induced an activated B cell response. Eighteen
of the 100 most differentially expressed genes were derived from
the B cell lineage. The up-regulated expression of transcripts
encoding the J chain, heavy-chain constant regions, and TNFRSF17,
when taken together with the more modest increased expression of
MS4A1 (CD20), CD19, TNFRSF13B, and TNFRSF13C, suggests
that this response is more a consequence of plasma cell dif-
ferentiation than an accumulation of B cells (Dataset S1). A
plasma cell transcriptional signature in breast and lung ade-
nocarcinomas has been shown to correlate with improved sur-
vival (25). This AMD3100-induced T and B cell response was
accompanied by transcriptional evidence for the development
of TLSs (Fig. 4 D and E and Dataset S1). The restriction of
CCL19 mRNA, which is expressed only by FRCs (26), to tumor
stromal cells that were FAP+, a marker not only of CAFs but
also of FRCs (15, 27), was demonstrated by fluorescent in situ
hybridization (FISH). The FAP+ cells expressing CCL19 in-
creased significantly from 5.8 to 25.7% (Fig. 4D), suggesting
either that CAFs were differentiating to FRCs within the tumor
microenvironment, or that FRCs were being recruited from a
source outside the tumors.
The INTIRE and Immune-Mediated Damage to Noninfected Tissues.
The similarity of the AMD3100-induced transcriptional changes
to those that characterize tumors with TLSs (Fig. 4E), micro-
satellite instable (MSI) CRC (Fig. 4F), and rejecting renal allo-
grafts (Fig. 4G) suggested that the inhibition of a single
chemokine receptor, CXCR4, may induce an integrated immune
reaction that is characteristic of noninfected, immunogenic tis-
sues. To assess the INTIRE, we developed based on prior
knowledge from the literature the INTIRE gene signature, which
was defined by 194 genes that together identify nine components
of innate and adaptive immunity (Dataset S2): Monocyte/mac-
rophage/DC/antigen presentation, T and NK cell accumulation,
T and NK effector cells, chemokines and chemokine receptors,
activated B cells (germinal center B cells) and plasma cells,
stromal/FRC/TLS, type I/III IFN response, and endothelial cells
(blood and lymphatic). AMD3100 treatment of MSS PDA and
MSS CRC patients induced the INTIRE gene signature
(Fig. 5A). Up-regulation of the INTIRE gene panel also was
associated with decreased expression of E2F target genes and
other genes involved in the G2M checkpoint, possibly indicating
a reduction in replicating cancer cells in the tumor. The INTIRE
gene signature also distinguished between rejecting and non-
rejecting renal allografts in two studies (28, 29), a prototypical
example of immunologically mediated damage to noninfected
tissue. Relative to MSS CRC, MSI CRC demonstrated the
INTIRE gene signature (Fig. 5A) (30, 31), but, in contrast to the
Table 1. Patient characteristics
Characteristic n = 26
Age, y
Mean 66
Range 50–76
Female sex, n (%) 9 (35)
Histology, n (%)
Pancreatic adenocarcinoma 10 (38)
Colorectal adenocarcinoma 15 (58)
Neuroendocrine cancer* 1 (4)
ECOG, n (%)
0 9 (35)
1 17 (65)
Lymphocyte count (109/L)
Median 1.41
Range† 0.82–2.31
Albumin < 35 g/L, n (%) 13 (50)
Sites of metastasis > 2, n (%) 16 (62)
Prior lines of chemotherapy, n (%)
0 1(4)
1 1(4)
2 16 (62)
≥3 8 (31)
*On central review of research biopsies, pathology consistent with neuro-
endocrine pancreatic cancer, excluded from later analysis.
†One patient had a low count at enrollment that normalized on day 1
preinfusion.
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effects of inhibiting CXCR4 in MSS CRC and MSS PDA, MSI
CRC did not exhibit decreased cell cycle gene expression
(Fig. 5A). The INTIRE gene signature was also present in tu-
mors from longer surviving patients in the data from the Pre-
diction of Clinical Outcomes from Genomic Profiles (PRECOG)
study (Fig. 5B) (25). In two studies of melanoma patients treated
with anti–PD-1 antibody after 28 d and 11 d, respectively (32,
33), and a study of melanoma patients treated with combination
anti–PD-1 plus anti–CTLA-4 antibodies (33), responders dem-
onstrated the INTIRE gene signature. Remarkably, the INTIRE
gene signature also distinguished between melanomas that
subsequently responded to treatment with anti–PD-1 antibody
from those that did not (32, 33) (Fig. 5 A and C). Finally, mel-
anomas in patients who were depleted of B cells by administra-
tion of anti-CD20 (34) demonstrated an attenuated INTIRE
gene signature (Fig. 5 A and D), exemplifying the integrated
nature of this immune response.
Immune-Mediated Anticancer Effects of AMD3100 Administration.
We examined the transcriptional changes in the paired biopsies
for evidence of intratumoral immune-mediated anticancer effects.
Changes in the mRNA levels in biopsies from each patient of
Fig. 4. The immunological effects in human CRC and PDA of treatment with AMD3100. Paired biopsy tissues were obtained from the same metastasis in each
patient before (pre-Rx) and after 7 d of continuous infusion of AMD3100. (A) Tissue sections were stained with fluorescent antibodies to pan-keratin (pan-CK)
to reveal cancer cells, and to CD8 to reveal cytotoxic T cells. White arrowheads designate CD8+ T cells within cancer cell islets, and red arrowheads designate
CD8+ T cells outside of cancer cell islets. (Scale bar, 50 μm.) (B) The presence of CD8+ T cells within cancer cell islets, assessed by staining with anti-CD8 antibody,
correlates with the CD8A mRNA levels, assessed by RNA-seq analysis, in tissues obtained from different pass biopsies of the same metastatic lesions. (C)
Immunological gene sets that identify T and NK cell accumulation, T and NK cell effector cells, activated B cells (germinal center B cells) and plasma cells are
enriched in genes up-regulated after treatment with AMD3100. (D) The expression of CCL19 and FAP in sections from paired biopsies was analyzed by FISH
using specific probes for mRNA of FAP and CCL19. The total counts of FAP+/CCL19+ cells, FAP+/CCL19− cells, and FAP−/CCL19+ cells are displayed. (Scale bar, 50
μm.) (E) The enrichment analysis for a TLS gene set (13) is shown. (F and G) Enrichment analyses are shown for those genes that (F) are differentially expressed
in rejecting compared to nonrejecting kidney allografts (28, 29) and (G) MSI compared to MSS CRC (30). (A–G) n = 14 comprising of PDA (n = 4) and CRC (n =
10) Statistical comparisons by Spearman’s rank correlation test (B), and by Fisher’s exact test (D): ****P < 0.0001.
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granzymes (GZM) A, B, H, K, and M, and perforin, which encode
the proteins that mediate killing by effector CD8+ T cells, sig-
nificantly inversely correlated with changes in the mRNA levels of
three genes uniquely expressed by cancer cells, CEACAM 5, 6,
and 7 (Fig. 6A), but not with noncancer-specific genes (SI Ap-
pendix, Fig. S9).
Next, we evaluated plasma biomarker evidence of anticancer
effects in all samples that passed the respective quality thresholds
for analysis. The plasma concentrations of the tumor-derived
markers, carcinoembryonic antigen (CEA) and carbohydrate
antigen 19-9 (CA 19-9), which are not validated as early-response
markers in immunotherapy trials, were not significantly changed
over the 7-d treatment period of the patients with AMD3100 (n =
15, P = 0.4). Next, we quantified circulating tumor DNA
(ctDNA). Levels of ctDNA have been shown to decrease when
patients respond to therapy (35–38). We evaluated ctDNA levels
at baseline and after 7 d of treatment with AMD3100 (Fig. 6B).
ctDNA levels were significantly reduced following treatment with
AMD3100 (n = 15, P = 0.033). Furthermore, plasma levels of
CXCL8, which has also been identified as a marker of tumor
Fig. 5. Comparative analyses of the INTIRE induced by AMD3100. (A) The heat map is shown of the enrichment analyses of nine gene sets representing
different immune components that characterize the INTIRE in different immunological contexts, along with E2F target genes and genes involved in the G2M
checkpoint. Gene set enrichment analyses demonstrating that genes up-regulated by treatment with AMD3100 are significantly enriched in B genes asso-
ciated with longer overall survival in cancer according to the PRECOG (25) study, (C) genes up-regulated in pretreatment biopsies from patients with mel-
anoma who responded to anti–PD-1 treatment vs. nonresponding patients (32, 33), and (D) genes down-regulated in biopsies of patients with melanoma
treated with anti-CD20 antibodies to induce B cell depletion (34). (A–D) n = 14 comprising of PDA (n = 4) and CRC (n = 10).
Fig. 6. Analyses of the anticancer effect induced by AMD3100 treatment. (A) Changes of mRNA expression in the paired biopsies obtained from each patient
with CRC (n = 10) and with PDA (n = 4) before and after treatment with AMD3100 for granzymes A, B, H, K, and M and perforin negatively correlate with
changes in the expression of CEACAM 5, 6, and 7. (B) Plasma ctDNA levels (n = 15) and (C) serum concentrations of CXCL8 (n = 18) pretreatment (pre-Rx) and
after 7 d of continuous infusion of AMD3100 are shown. Statistical comparisons by Spearman’s rank correlation test (A), by paired Wilcoxon signed-rank test
(B), and by paired t test (C): *P < 0.05; ****P < 0.0001.
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burden (39) and may provide an early indicator of therapeutic
response (39–41), were also significantly decreased following
treatment with AMD3100 (Fig. 6C) (n = 18, P < 0.0001). The
decrease in both ctDNA and CXCL8 levels support the possibility
of an early anticancer effect mediated by CXCR4 inhibition.
Discussion
The findings that the CAF mediates intratumoral immune sup-
pression (18, 20) and that a CAF-derived chemokine, CXCL12,
coats the cancer cells in PDA and CRC suggest that its receptor,
CXCR4, has a role in mediating immune suppression in the
tumor microenvironment. The association of CXCL12 with
cancer cells is predicted to have two immunological conse-
quences. First, most immune cells in PDA and CRC tumors
express CXCR4 and will, therefore, be stimulated by cancer cell-
associated CXCL12 via ligation of this receptor. Second,
CXCL12-stimulated CXCR4 inhibits the chemotactic functions
of the chemokine receptors that direct the migration of immune
cells. Therefore, the CXCL12-coat of cancer cells could impair
the intratumoral accumulation of multiple immune cell types.
We tested these two predictions in an experimental medicine
study in which patients with PDA and CRC received the small-
molecule CXCR4 antagonist, AMD3100, which is licensed for
mobilization of HSCs.
Treatment of patients with AMD3100 was limited to contin-
uous intravenous infusion of the drug for 1 wk, using a protocol
shown to be safe in patients with HIV (23). We first confirmed
that the AMD3100 infusion did achieve continuous CXCR4 in-
hibition by observing the presence of CD34+ HSCs in the pe-
ripheral blood of each patient. All patients from the dose-
escalation phase showed persistent elevations of CD34+ HSCs,
indicating the occurrence of continuous CXCR4 inhibition, and
we therefore included patients from the entire cohort in all
subsequent analyses. The short duration of drug administration
limited our ability to observe whether CXCR4 inhibition induced
clinical responses in patients with PDA or CRC, as assessed by
standard radiological evaluations (42, 43). These assessments did
not reveal remissions and the lack of change in tumor volume is
not informative due to the short time period that elapsed be-
tween scans. An independent clinical trial testing discontinuous
CXCR4 inhibition by subcutaneous administration of a cyclic
peptide inhibitor of CXCR4 together with anti–PD-1 antibody
over several cycles in patients with advanced pancreatic cancer
showed some evidence of clinical responses (44). We observed
significant decreases in the levels of ctDNA and circulating
CXCL8 of patients after treatment with AMD3100. ctDNA and
CXCL8 are increasingly recognized as markers of tumor burden
(35, 38, 39) and may provide early indications of response to
therapy (35–41) when imaging evaluation is not conclusive (42,
43). However, these initial observations will require further
prospective validation.
This study focused on the question of whether the CXCL12-
coating of cancer cells in PDA and CRC signified the existence
of a fundamental immune suppressive pathway in two human
cancers that have thus far resisted cancer immunotherapy. We
chose to detect immunological changes by performing bulk
RNA-seq analysis of paired biopsies of metastatic lesions taken
from patients before and at the end of the AMD3100 infusion.
This analysis provided an unbiased and quantitative means of
measuring the AMD3100-induced changes in the complex
intratumoral immune environments of these tumors, which could
be compared to similar transcriptional analyses of tissues rep-
resenting other immunological reactions.
This comparative transcriptional analysis revealed unantici-
pated similarities between the immunological effects of two
mechanistically distinct immunotherapies, inhibition of T cell
checkpoints and inhibition of a chemokine receptor, respectively,
in cancers that have different developmental origins, adenocarcinomas,
and melanomas. Both anti–PD-1 and anti–CTLA-4 antibody
therapies, which enhance the activation of T cells, and AMD3100
treatment, which affects the trafficking of immune cells, up-
regulated the expression of genes that characterize rejecting
renal allografts, an example of immune damage to immunogenic,
noncancer tissue. Thus, effective cancer immunotherapy engages
an immune pathway that mediates damage to noninfected, im-
munogenic tissue. This pathway involves multiple immune ele-
ments, and their participation could be assessed by the INTIRE
signature, which characterizes nine components of the immune
reaction. This analysis showed that the INTIRE signature was
induced not only by CXCR4 inhibition in patients with PDA and
CRC, but also by successful treatment of patients with melanoma
with anti–PD-1 antibody. The occurrence of the INTIRE sig-
nature was even predictive of subsequent clinical responses to
anti–PD-1 antibody therapy in patients with melanoma. The
additional finding that AMD3100 leads to the increased fre-
quency of FAP+ cells expressing CCL19, which is a characteristic
of FRCs, is consistent with the concept that shifting the balance
from immune suppressive fibroblastic cells to those with immune-
enhancing functions improves the outcome of cancer immuno-
therapy. This observation is reminiscent of the recent reports
that the presence of TLSs, which in the mouse requires FAP+
fibroblasts (15, 45), correlates with clinical responses to T cell
checkpoint therapy (11–13).
Finally, the study raises the possibility that a substantial pro-
portion of patients with MSS PDA and MSS CRC have on-going
anticancer immune responses. A majority of the patients treated
with AMD3100 showed enhanced intratumoral immune B and
T cell responses after only 7 d, which would be unusually rapid
for a primary immune response. Thus, intratumoral immune
suppression rather than immune ignorance may be a major
barrier to clinically effective immunotherapy. This possibility
should be assessed with an appropriate clinical trial of repeat
cycles of continuous CXCR4 inhibition in combination with a
T cell checkpoint antagonist.
Methods
Immunofluorescence of Human Tumor Arrays. FFPE human pancreatic and
colorectal tumor arrays (US Biomax) were deparaffinized in xylene, washed
three times with ethanol, and rehydrated in a serial concentration of ethanol
(from 95 to 50%), and finally in water. For antigen retrieval, the sections were
boiled in 10 mM Tris, pH 8.8 plus 1 mM EDTA for 10 min, followed by cooling
down for 30 min, a wash with PBS, and blocking with 1% BSA/PBS at room
temperature for 1 h. Following two washes with 0.05% Tween-20/PBS and
one with PBS, Alexa Fluor 568-conjugated anti-KRT19 antibody (Abcam,
ab203445) and FITC conjugated anti-CXCL12 antibody (R&D Systems, IC350F)
were applied and the sections were incubated at room temperature for 1 h.
Finally, the sections were stained with DAPI (Thermo Fisher, R37606) for
10 min and washed with 0.05% Tween-20/PBS for two times and once with
PBS, followed by application of mounting medium (Thermo Fisher, P36961)
and imaging with Leica SP8 confocal microscope. Images were analyzed and
exported through ImageJ.
Chemotaxis Assays.
Plasmids. To generate lentiviral plasmid expressing human chemokine re-
ceptors, CXCR1 and CXCR3 cDNA from CXCR1-Tango (Addgene, #66259) and
CXCR3-Tango (Addgene, #66261), respectively, were amplified and subcl-
oned into lentiCas9-blast (Addgene, #52962) with restriction enzymes Age1
and BamH1 to replace SpCas9; CXCR5 and CXCR6 cDNA from CXCR5-Tango
(Addgene, #66263) and CXCR6-Tango (Addgene, #66264), respectively, were
amplified and subcloned into lentiCas9-puro to replace SpCas9 where
blasticidin-resistant gene (blast) was also replaced with puromycin-resistant
gene (puro). For CRISPR editing, control guide (sgScramble, GCTTAGTTACGC-
GTGGACGA) and guides targeting to human CXCR4 gene (sgCXCR4-1, TGA-
CATGGACTGCCTTGCAT; sgCXCR4-2, CAACCACCCACAAGTCATTG; sgCXCR4-3,
CAGGACAGGATGACAATACC) or human RGS14 gene (sgRGS14-1, GCAGGG-
ATCTGTGAGAAACG; sgRGS14-2, TCGGCAGCCCTGACGCCACG; sgRGS14-3, CTG-
AGACTCTCGGCGCAAGG) were cloned into the vector lentiCRISPR-v2
(Addgene, #62961).
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Cell lines. Jurkat cells (ATCC, Clone E6-1, TIB-152) were transduced with
lentivirus expressing human CXCR1, CXCR3, or CXCR6, followed by treat-
ment with 5 μg/mL blasticidin (CXCR1 and CXCR3) or 0.5 μg/mL puromycin
(CXCR6) for 2 wk, to generate Jurkat-CXCR4/CXCR1 cells, Jurkat-CXCR4/
CXCR3 cells and Jurkat-CXCR4/CXCR6 cells, respectively. For Raji B-CXCR4/
CXCR5 cells, Raji B cells (ATCC, CCL-86) were transduced with CXCR5 lenti-
virus followed by selection with 0.5 μg/mL puromycin for 2 wk. Subpopula-
tion of CCRF-HSB-2 cells (ATCC, CCL 120.1) that spontaneously express a high
level of CXCR3 were FACS sorted as HSB2DP-CXCR4/CXCR3 cells, where DP
stands for “double positive.” The Molm13 cell line (Molm13-CXCR4/CCR2),
which expresses both CXCR4 and CCR2 spontaneously, was a gift from C.
Vakoc’s laboratory, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
For CRISPR knock-outs, Jukat-CXCR4/CXCR3 and Molm13-CXCR4/CCR2 cells
were transduced with lentivirus expressing SpCas9 and control guide
(sgScramble), guides targeting to CXCR4 (sgCXCR4) or RGS14 (sgRGS14).
HSB2DP-CXCR4/CXCR3 cells were cultured in IMDM medium (ATCC, 30-2005)
supplemented with 10% FBS (Seradigm, 1500-500), 100 units/mL penicillin
and 100 μg/mL streptomycin. All of the other cell lines were cultured in
RPMI-1640 medium (ATCC, 30-2001) plus 10% FBS and penicillin/strepto-
mycin. Cells were maintained at the density of 1 × 105 to 1 × 106 cells/mL
Flow cytometry. For each cell line, 1 × 105 to 1 × 106 cells were pellet and
washed with cold FACS buffer (PBS, 2% FBS, and 20 mM Hepes, pH 7.4),
followed by Fc receptor blocking with Human TruStain FcX (BioLegend,
422301) in the FACS buffer at 4 °C for 30 min. Cells were then stained with
APC-conjugated anti-Human CXCR4 antibody (BioLegend, 306510) and/or
Alexa Fluor 488-conjugated anti-Human CXCR1 antibody (BioLegend,
320616), PE-conjugated anti-Human CXCR3 antibody (BioLegend, 353706),
FITC-conjugated anti-Human CCR2 antibody (BioLegend, 357215), FITC-
conjugated anti-Human CXCR5 antibody (BioLegend, 356913), APC-
conjugated anti-Human CXCR6 antibody (R&D Systems, FAB699A) for an-
other 30 min at 4 °C. Then, cells were washed with the FACS buffer twice and
analyzed with an BD LSRForsseta cell analyzer.
Chemotaxis assays. The chemotaxis buffer for HSB2DP-CXCR4/CXCR3 cells is
IMDMmedium plus 0.1% BSA and 20 mM Hepes, pH 7.5 and for all other cell
lines is RPMI-1640 medium plus 0.1% BSA and 20 mM Hepes, pH 7.5. After
collection, cells were washed two times and resuspended in the chemotaxis
buffer at the density of 1 × 106/mL, followed by incubation at 37 °C for
30 min. For the CXCL12 cross-inhibition of the other chemokine-induced
chemotaxis, 80 μL cells with or without 100 ng/mL (200 ng/mL for CCR2)
recombinant human CXCL12 (R&D Systems, 350-NS) were loaded in the
upper wells of the Boyden chamber plate (VWR, 89089-934; Supplier no.
3388; 5-μm membrane pore size), and the lower chambers were flowed in
240 μL chemotaxis buffer with PBS or the other specific recombinant human
chemokine. To test the effect of other specific chemokine on the CXCL12-
induced chemotaxis, cells and the specific chemokine were loaded on the
upper chamber, with CXCL12 containing chemotaxis buffer loaded in the
lower chamber. To evaluate the activity of AMD3100 (Sigma, A5602) on
CXCL12 or the other specific chemokine-induced chemotaxis, cells were
pretreated with increasing dose of the drug at 37 °C for 30 min, then the
cell/AMD3100 mixture was loaded in the upper chambers, and CXCL12 or
other specific chemokine containing chemotaxis buffer was loaded in the
lower chambers. For the AMD3100 rescue of the CXCL12 mediated cross-
inhibition, the AMD3100 pretreated cells together with 100 ng/mL CXCL12
were loaded in the upper chambers, and chemotaxis buffer containing the
other specific chemokine was flowed in the lower chambers. After the ex-
periments were set up, the Boyden chamber plates were incubated at 37 °C
for 2 or 3 h. Then, the number of cells in the lower chamber was counted
with a Guava bench-top flow cytometer, for 30 s at medium flow rate (∼1.2
μL/s). The concentration of each chemokine used is as following: CXCL8 (R&D
Systems, 208-IL), 20 ng/mL; CXCL10 (R&D Systems, 266-IP), 1,000 ng/mL;
CXCL13 (R&D Systems, 801-CX), 1,000 ng/mL; CXCL16 (R&D Systems, 976-CX),
50 ng/mL; CCL2 (R&D Systems, 279-MC), 200 ng/mL
RNA-Seq Analysis.
Gene-expression quantification and differential gene-expression analysis. Se-
quences of human transcripts were downloaded from Ensembl release 97.
Transcript quantification was performed using Kallisto v0.43 and gene-level
count matrices for use in DESeq2 were calculated using tximport as recom-
mended by DESeq2 authors (46). All subsequent analyses on gene expression
were performed using R 3.5.0. For differential expression analysis, raw
counts were used directly in DESeq2. For other downstream analyses
(i.e., fold-change correlation plots) counts data were transformed using the
variance stabilizing transformation as implemented in DESeq2.
Gene set enrichment analysis. Gene set enrichment analysis was performed
using the fgsea package available in Bioconductor. Gene set enrichment
analysis plots were obtained using a modified version of the associated
plotEnrichment function. All gene sets used in the manuscript are provided
as supplementary tables. Data used for Fig. 5A were obtained from several
different sources: The rejecting allografts gene list was obtained from Gene
Expression Omnibus (GEO) series GSE48581 (29) and GSE36059 (28); the
microsatellite instability gene list was obtained by combining Xena Univer-
sity of California, Santa Cruz (UCSC) TCGA gene expression data (31) and MSI
status for the same tumor samples (30); the list of genes associated with pan-
cancer survival was obtained from the PRECOG portal (25); the anti–PD-1
response gene lists were obtained from the GEO: GSE91061 (32) and Euro-
pean Nucleotide Archive: PRJEB23709 (33); the anti-CD20 gene list was
obtained from Array Express: E-MTAB-7473 (34).
Code availability. The authors declare that the R code used to generate the
analysis presented in this study is available in Dataset S3.
Experimental Medicine Study.
Patient eligibility. Patients with advanced or metastatic PDA, high-grade serous
ovarian cancer, or CRC, refractory to or declining conventional chemother-
apy were eligible for the dose-escalation phase. The 10-patient expansion
cohort at the recommended phase 2 dose (RP2D) of 80 μg/kg/h was restricted
to patients with PDA. Other eligibility criteria included a lesion accessible to
biopsy, Eastern Cooperative Oncology Group (ECOG) performance status of
0 or 1, and adequate organ function, including a lymphocyte count above
the lower limit of normal. Patients were excluded if they had significant
cardiac comorbidities, such as past history of significant rhythm disturbance.
Full eligibility criteria can be viewed at https://clinicaltrials.gov/ct2/show/
NCT02179970. Patients were accrued at Cambridge University Hospitals NHS
Foundation Trust and Weill Cornell Medicine/New York Presbyterian
Hospital, NY.
Study design. This phase 1, multicentre, open-label, nonrandomized study
used a 3+3 dose-escalation design. The primary endpoint was the safety
(evaluated using the Common Terminology Criteria for Adverse Events 4.03)
of AMD3100 administered, to achieve a plasma AMD3100 concentration at
steady state ≥2 μg/mL in ≥80% of patients at the RP2D. AMD3100 was ad-
ministered as a 7-d continuous infusion. DLT was defined as an adverse re-
action (AR) ≥G3 occurring within 21 d of AMD infusion. Secondary endpoints
included overall response rate (RECIST 1.1) at 14 (±2) d after the infusion,
and metabolic changes in tumor using [18F]FDG-PET/CT within 1 d of infusion
completion. Baseline scans were performed within 14 d before the start of
the infusion. Exploratory objectives included the assessment of immune
changes in tumor biopsies. Patients were monitored by cardiac telemetry for
the initial 48 h of the infusion (later amended to 72 h), followed by Holter
monitoring for the remainder of the infusion.
Patients providedwritten informed consent to Research Ethics Committee-
approved protocol (REC reference 15/EE/0014 at the United Kingdom Center
and Institutional Review Board no. 1508016466 at the United States Center),
in compliance with Good Clinical Practice, local regulatory requirements,
and legal requirements. A clinical trial authorization was obtained from the
Medicine and Healthcare Regulatory Authority. The study was sponsored by
Cambridge University Hospitals NHS Foundation Trust and the University of
Cambridge and Weill Cornell Medicine/New York Presbyterian Hospital.
AMD3100 sample and pharmacokinetic analysis. AMD3100 plasma concentration
was assessed at the following nominal time points: Predose, 24, 72, and 168 h
of the infusion. A time point at day 7 (±2) after infusion discontinuation was
added from patient 1017 onwards. The concentration data were generated
using a liquid chromatography-tandem mass spectrometry (LC-MS/MS)
method, that met the requirements of the European Medicines Agency
guidance on method validation, performed by the Cancer Research UK
Cambridge Institute PK/Bioanalytics Core Facility. A claim of Good Clinical
Practice compliance is made for the sample analysis data, pending the
demonstration of long-term storage stability, which is on-going at the time
of publication. AMD3100 calibration standards were prepared in the range
of 40 to 4,000 ng/mL using blank control human plasma obtained from the
NHS blood transfusion service (lower limit of quantification 40 ng/mL). After
the addition of the internal standard (AMD3100-D4) and EDTA (10 mM),
plasma samples, quality control (QC), and calibration standards were
extracted by protein precipitation with 1% formic acid in methanol. A
portion of the supernatant was evaporated to dryness and the residue
reconstituted in 1% formic acid in water prior to analysis on the LC-MS/MS.
HPLCγ was performed with the Shimadzu Nexera ×2 using a Phenomenex
Kinetex F5 column (1.7 μm, 100 × 2.1 mm) and mobile phases A and B
containing 0.1% formic acid in water or methanol, respectively. MS/MS de-
tection was carried out using a Sciex API6500 mass spectrometer with an
electrospray source. QC samples (120, 400, and 3,000 ng/mL) were used to
determine the precision (coefficient of variation [%CV]) and accuracy
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(relative error [%RE]). QC intraday %CV was ≤9.8%, and %RE ranged be-
tween −3.1 to 4.8%. All instrument control and data collection were per-
formed using Analyst v1.6.2, and peak area integration, regression and
quantification using MultiQuant v3.0.2. A weighted (1/×2) least-square lin-
ear regression was used to construct the calibration line.
Pharmacodynamic Analysis. At baseline, 24/72/168 h of the infusion, and
21(±2) d after infusion, blood was collected into Sarstedt EDTA blood tubes
and CD34+ cells quantified by flow cytometry. The CD34+ absolute count was
derived from a bead-based assay using BD Bioscience Trucount tubes and an
International Society of Hematotherapy and Graft Engineering gating strategy.
Positron Emission Tomography. PET was performed in conjunction with low-
dose CT for attenuation correction and localization purposes. Images were
acquired from the midbrain to the knees, ∼90 (89.7 ± 21.1) min after the
injection of ∼370 (368 ± 13) MBq of [18F]fluorodeoxyglucose ([18F]FDG). The
baseline [18F]FDG-PET/CT was performed before or at least 24 h after the
core tissue biopsy, and the posttreatment PET-CT was performed within 24 h
after the biopsy on day 8 of the study. Nineteen patients underwent im-
aging at both timepoints and were evaluated for metabolic changes fol-
lowing treatment. Response was determined by calculating the change in
SUV MWA of the [18F]FDG avid target lesions. SUV MWA was calculated as
the sum of the product of the SUV mean 75% and volume for all target
lesions, divided by the total target lesion volume. A clinically significant
change was defined as change in SUV MWA ≥ 30%.
Biopsy Processing.
RNA and DNA extraction. Snap-frozen biopsies were embedded in chilled OCT
(−4 °C) and allowed to solidify in a cryotome at −20 °C. Subsequently, 10 30-
μm sections were cut and collected in RLT buffer for DNA/RNA extraction,
followed by six 6-μm sections for histologic analysis. The remaining tissue
was cut in 30-μm sections until exhausted. All 30-μm sections were extracted
for DNA and RNA using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen,
80224) according to the manufacturer’s instructions from tissues, and DNA
quantification by fluorometer according to manufacturer instructions (Qubit
3.0, Life Technologies). An H&E was reviewed by a histopathologist to de-
termine cellular content (>40% cancer cell content).
Histopathologic analyses. For histopathologic analyses, 3-μm FFPE tissue sec-
tions were deparaffinized in xylene and rehydrated in an ethanol series.
Immunofluorescence staining was performed on the Bond Rx automated
platform. Sections were retrieved with Tris EDTA for 20 min and incubated
sequentially with primary and secondary antibody pairs (where applicable)
at room temperature for 30 min or, for CXCL12, 60 min. Slides were coun-
terstained with DAPI and digitalized using the Axio Scan.Z1 (Zeiss) at 20 ×
(0.22 μm per pixel). Tumor areas were selected based on review of serial H&E
sections by a histopathologist: Liver, peritoneal fat, and necrosis were ex-
cluded. The HighPlex FL v3.0.1 algorithm in Halo software (v2.3, Indica Labs)
was used to automatically detect CD8+ cells across all sections, with a tissue
classifier that restricted analysis to pan-CK+ areas within the predefined
tumor area. The same algorithm was used for pre- and posttreatment bi-
opsies. Cell counts were normalized to pan-CK tissue area (cells μm−2).
Primary antibodies were: CD8 (SP16; Lab Vision/Thermo Scientific), pan-
cytokeratin (AE1/AE3 Alexa Fluor 488 conjugate; eBioscience), and CXCL12
(79018; R&D Systems).
Immunological Assays.
Fluorescent in situ hybridization. RNAscope (Advanced Cell Diagnostics) was
performed following the standard protocol. Frozen sections were fixed with
4% paraformaldehyde (PFA) for 15 min at 4 °C and dehydrated with se-
quential ethanol solution (50 to 100%) at room temperature. Sections were
incubated with pretreat IV for 30 min and washed in PBS before being hy-
bridized with gene-specific probes (CCL19, FAP) for 2 h at 40 °C in a HybEZ
oven. Sections were washed with wash buffer followed by incubations in
sequential amplifers (Amp1–Amp4). Finally, sections were stained with DAPI
and mounted with prolong antifade mountant. Images were taken by Leica
SP8 confocal microscope and analyzed with ImageJ software.
Plasma Cell-Free DNA Analysis. Blood samples were collected into EDTA-
containing tubes and processed by a double-centrifugation protocol
(1,600 × g for 10 min; 14,000 rpm for 10 min) before storage at −80 °C. Plasma
DNA was extracted using QIAsymphony DSP Circulating DNA Kit (Qiagen) and
DNA-sequencing libraries were prepared using the ThruPLEX Plasma-seq kit
(Takara Bio). Unique DNA barcode sequences were introduced to allow
pooled sequencing runs on HiSeq 4000 (Illumina) generating 150-bp long
paired-end reads. Sequencing reads were subsequently aligned to the human
reference genome (hg19) using BWA-mem. PCR and optical duplicates were
marked using MarkDuplicates (Picard Tools) and excluded from downstream
analysis along with reads of low mapping quality. Sequencing data in each
sample were downsampled to 5 million reads to generate t-MAD scores (47)
for estimating ctDNA levels inferred from a genome-wide copy number ab-
erration profile. The segmentation step was summarized by a median value
and a t-MAD threshold of 0.015 was used.
CytokineAnalysis. Serumwas analyzed for CXCL8 using theMesoScaleDiscovery
Human 10-plex ProInflammatory Panel 1 kit (V-PLEX K15049D-2), as per the
manufacturer’s instructions. Analyses were conducted at the Core biochemical
assay laboratory at Cambridge University Hospitals, NHS Foundation Trust.
Data Availability. All study data are included in the article and supporting
information.
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